Preliminary data shows Vaxzevria given as third dose ups antibody response to Omicron: AstraZeneca
The Hindu
The results were observed among individuals previously vaccinated with either Vaxzevria or an mRNA vaccine.
New Delhi Biopharmaceutical multinational AstraZeneca on Thursday said the preliminary analysis of an ongoing safety and immunogenicity trial has indicated that Vaxzevria, when given as a third dose booster, increased antibody response to the Omicron variant.
The study also noted that the booster dosage of the company’s COVID-19 vaccine Vaxzevria also increased the immune response to Beta, Delta, Alpha and Gamma SARS-CoV-2 variants.
The results were observed among individuals previously vaccinated with either Vaxzevria or an mRNA vaccine.
More Related News